相关实验视频

Updated: Jun 14, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

慢性心力衰竭和高尿血症患者的外体miRNAs以及潜在的机制

Zhiliang Chen¹, Jun Shi², Xia Huang¹

¹Department of Cardiology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, PR China.

|September 6, 2024

概括

新的生物标志物,外体miR-27a-5p和miR-139-3p,可以精确诊断慢性心力衰竭 (CHF) 与高尿血 (HUA). 这些miRNA与AMPK-mTOR通路有关,这表明它们在疾病发病过程中起作用.

科学领域:

生物化学生物化学
分子生物学分子生物学
心血管医学心血管医学

背景情况:

慢性心力衰竭 (CHF) 和高尿路血症 (HUA) 经常共存,这给诊断带来了挑战.
外体微RNAs (miRNAs) 涉及到心血管疾病和生物调节.
目前还缺乏用于诊断CHF与HUA结合的单一生物标志物.

研究的目的:

为了确定新的分子标记,用于精确诊断CHF与HUA结合.
分析差异表达的miRNAs的潜在目标.
为了研究miRNAs在CHF病变发生过程中的作用,与HUA结合.

主要方法:

这是一项对照性研究,对比了30名心血管疾病患者的HUA (T组) 和30名健康志愿者 (C组).
从周围血液中对外体miRNA进行高通量测序,然后进行RT-PCR验证.
基因本体学 (GO) 和KEGG途径分析以预测miRNA目标和相关途径.

主要成果:

鉴定了42种差异表达的miRNA,包括T组上调的miR-27a-5p和下调的miR-139-3p (P<0.01).
对miR-27a-5p和miR-139-3p的联合检测实现了0.899的AUC,用于诊断HUA的CHF.
丰富分析表明,在AMPK-mTOR信号通路中,有差异表达的miRNA参与,激活了自性.

结论:

上调的外体miR-27a-5p和下调的外体miR-139-3p作为精确CHF与HUA诊断的新型分子标志物.
通过AMPK-mTOR信号通路增强的自可能有助于结合HUA的CHF的发病.
这些发现为这种共同疾病背后的分子机制提供了新的见解.

关键词:

由AMP激活的蛋白激酶酶 (AMP) 激活的蛋白激酶 (AMP) 激活的蛋白激酶这是心脏衰竭.超性血症 (hyperuricemia) 是一种疾病,微RNAs是一种微RNA.在TOR中,氨酸-氨酸激酶 (Serine-Threonine Kinases) 发生.

更多相关视频

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

相关概念视频

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...